#Shanghai #None #biotechnology #Series A #OTR Therapeutics

OTR Therapeutics Secures $100 Million in Series A Financing

OTR Therapeutics, a promising biotechnology firm, has made headlines with its recent achievement of raising $100 million through a Series A financing round, which concluded in June 2025. This funding round was notably supported by several reputable investors, including True Light Capital (a subsidiary of Temasek), LAV, Pfizer Ventures, and Sirona Capital. With this financial backing, OTR aims to advance its mission of translating early-stage medical innovations into therapies that can make a significant impact globally.

Founded in March 2025, OTR Therapeutics is on a mission to create a scalable and capital-efficient model that marries internal research and development (R&D) efforts with a strategic focus on promising external innovations. By doing so, the company positions itself to push the boundaries of scientific discovery while remaining agile in its operations. OTR's approach is enhanced by its deep understanding of regional scientific ecosystems, which it seeks to leverage for expediting the delivery of innovative therapies to patients worldwide.

The funds raised will primarily be allocated to expanding OTR's portfolio of programs, which target unresolved gaps in critical areas such as immunology and inflammation, oncology, and a myriad of other disease categories. Additionally, the financing will bolster OTR’s R&D capabilities, focusing not only on scientific excellence but also on fostering strategic partnerships that can accelerate the development of high-impact therapies.

OTR Therapeutics also recently announced the acquisition of a preclinical program that presents exceptional potential for treating neurological disorders with significant unmet needs. This strategic acquisition is part of their ongoing efforts to identify and promote early-stage assets while complementing their internal discovery initiatives. OTR's objective is to broaden the spectrum of therapeutic solutions addressing serious patient needs.

Dr. Zhui Chen, the Founder and CEO of OTR Therapeutics, commented on the evolving landscape of global pharmaceutical research and development.